New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.